Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology

Simple Summary The clinical success of cancer immunotherapy targeting immune checkpoints (e.g., PD-1, CTLA-4) has ushered in a new era of cancer therapeutics aimed at promoting antitumor immunity in hopes of offering durable clinical responses for patients with advanced, metastatic cancer. This success has also reinvigorated interest in developing tumor model systems that recapitulate key features of antitumor immune responses to complement existing in vivo tumor models. Patient-derived tumor models have emerged in recent years to facilitate study of tumor–immune dynamics. Microfluidic technology has enabled development of microphysiologic systems (MPSs) for the evaluation of the tumor microenvironment, which have shown early promise in studying tumor–immune dynamics. Further development of microfluidic-based “tumor-on-a-chip” MPSs to study tumor–immune interactions may overcome several key challenges currently facing tumor immunology. Abstract Recent advances in cancer immunotherapy have led a paradigm shift in the treatment of multiple malignancies with renewed focus on the host immune system and tumor–immune dynamics. However, intrinsic and acquired resistance to immunotherapy limits patient benefits and wider application. Investigations into the mechanisms of response and resistance to immunotherapy have demonstrated key tumor-intrinsic and tumor-extrinsic factors. Studying complex interactions with multiple cell types is necessary to understand the mechanisms of response and resistance to cancer therapies. The lack of model systems that faithfully recapitulate key features of the tumor microenvironment (TME) remains a challenge for cancer researchers. Here, we review recent advances in TME models focusing on the use of microfluidic technology to study and model the TME, including the application of microfluidic technologies to study tumor–immune dynamics and response to cancer therapeutics. We also discuss the limitations of current systems and suggest future directions to utilize this technology to its highest potential.

[1]  H. Clevers,et al.  Intestinal organoid cocultures with microbes , 2021, Nature Protocols.

[2]  Dong Woo Lee,et al.  3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity , 2021, Communications Biology.

[3]  Shuqiang Li,et al.  Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma , 2021, Nature.

[4]  N. Almog,et al.  Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. , 2021, Cancer cell.

[5]  E. Cuppen,et al.  Prospective experimental treatment of colorectal cancer patients based on organoid drug responses , 2021, ESMO open.

[6]  J. Brandner,et al.  Melanoma Associated Chitinase 3-Like 1 Promoted Endothelial Cell Activation and Immune Cell Recruitment , 2021, International journal of molecular sciences.

[7]  T. Ho,et al.  Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer , 2021, Cells.

[8]  Jin-Ha Choi,et al.  Microfluidic System to Analyze the Effects of Interleukin 6 on Lymphatic Breast Cancer Metastasis , 2021, Frontiers in Bioengineering and Biotechnology.

[9]  D. Beebe,et al.  Elucidating cancer-vascular paracrine signaling using a human organotypic breast cancer cell extravasation model. , 2021, Biomaterials.

[10]  N. London,et al.  Organoid and Spheroid Tumor Models: Techniques and Applications , 2021, Cancers.

[11]  R. Breakstone.  Colon cancer and immunotherapy-can we go beyond microsatellite instability? , 2021, Translational gastroenterology and hepatology.

[12]  L. Weiner,et al.  3D Culture Systems for Exploring Cancer Immunology , 2020, Cancers.

[13]  Clifford A. Meyer,et al.  In Vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target , 2020, bioRxiv.

[14]  K. Flaherty,et al.  Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  D. Olive,et al.  3D Tumor Models and Their Use for the Testing of Immunotherapies , 2020, Frontiers in Immunology.

[16]  S. Niclou,et al.  Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy , 2020, Frontiers in Oncology.

[17]  S. Achilefu,et al.  Calcium carbonate nanoparticles stimulate cancer cell reprogramming to suppress tumor growth and invasion in an organ-on-a-chip system , 2020, Scientific Reports.

[18]  Manuel Doblaré,et al.  Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution , 2020, Scientific Reports.

[19]  Marcel A. Heinrich,et al.  3D In Vitro Model (R)evolution: Unveiling Tumor-Stroma Interactions. , 2020, Trends in cancer.

[20]  M. Saito,et al.  The future of microfluidics in immune checkpoint blockade , 2020, Cancer Gene Therapy.

[21]  S. Gygi,et al.  3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. , 2020, Molecular cell.

[22]  Andrey Rzhetsky,et al.  Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids , 2020, Nature Communications.

[23]  Y. Tabata,et al.  Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening , 2020, Cancers.

[24]  A. Jacinto,et al.  Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies , 2020, Frontiers in Oncology.

[25]  Luke T. Dang,et al.  Next-Generation Surrogate Wnts Support Organoid Growth and Deconvolute Frizzled Pleiotropy In Vivo. , 2020, Cell stem cell.

[26]  A. Jimeno,et al.  Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells , 2020, Cancer Research.

[27]  Ibrahim T. Ozbolat,et al.  3D bioprinting for reconstituting the cancer microenvironment , 2020, npj Precision Oncology.

[28]  J. Netterville,et al.  Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids , 2020, iScience.

[29]  Jianhong Ou,et al.  Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis , 2020, Nature Cell Biology.

[30]  C. Kuo,et al.  Organoid Models of Tumor Immunology , 2020, Trends in immunology.

[31]  A. Wellstein,et al.  Monitoring Cancer Cell Invasion and T-Cell Cytotoxicity in 3D Culture. , 2020, Journal of visualized experiments : JoVE.

[32]  Vianne R. Gao,et al.  Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer , 2020, Cancer cell.

[33]  J. Moffat,et al.  The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. , 2020, Cell stem cell.

[34]  Y. Tabata,et al.  A co-culture model of 3D TAM and 3D CAF combined with biomolecules release for cancer cell migration. , 2020, Tissue engineering. Part A.

[35]  D. Beebe,et al.  Breast Fibroblasts and ECM Components Modulate Breast Cancer Cell Migration through the Secretion of MMPs in a 3D Microfluidic Co-Culture Model , 2020, Cancers.

[36]  D. Fisher,et al.  Treatment of Advanced Melanoma in 2020 and Beyond. , 2020, The Journal of investigative dermatology.

[37]  R. Verma,et al.  Organotypic cancer tissue models for drug screening: 3D constructs, bioprinting and microfluidic chips. , 2020, Drug discovery today.

[38]  Xiang Ren,et al.  Breast cancer models: Engineering the tumor microenvironment. , 2020, Acta biomaterialia.

[39]  B. Vincent,et al.  Interleukin-23 engineering improves CAR T cell function in solid tumors , 2020, Nature Biotechnology.

[40]  G. Freeman,et al.  The importance of exosomal PDL1 in tumour immune evasion , 2020, Nature Reviews Immunology.

[41]  Gerry L. Koons,et al.  3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization. , 2020, ACS biomaterials science & engineering.

[42]  D. Speiser,et al.  LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures , 2020, Oncoimmunology.

[43]  Zev A. Binder,et al.  A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity , 2019, Cell.

[44]  H. Clevers,et al.  Organoids in immunological research , 2019, Nature Reviews Immunology.

[45]  S. Varghese,et al.  An engineered tumor-on-a-chip device with breast cancer-immune cell interactions for assessing T-cell recruitment. , 2019, Cancer research.

[46]  P. Dittrich,et al.  Single-cell protein profiling in microchambers with barcoded beads , 2019, Microsystems & Nanoengineering.

[47]  D. Beebe,et al.  Neutrophil trafficking on-a-chip: an in vitro, organotypic model for investigating neutrophil priming, extravasation, and migration with spatiotemporal control. , 2019, Lab on a chip.

[48]  F. de Nigris,et al.  Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors , 2019, British Journal of Cancer.

[49]  T. Schlange,et al.  Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC , 2019, Cells.

[50]  P. Decuzzi,et al.  Two-Channel Compartmentalized Microfluidic Chip for Real-Time Monitoring of the Metastatic Cascade. , 2019, ACS biomaterials science & engineering.

[51]  T. Schumacher,et al.  Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold , 2019, Cell.

[52]  Wei Sun,et al.  Three‐dimensional microfluidic tumor–macrophage system for breast cancer cell invasion , 2019, Biotechnology and bioengineering.

[53]  P. Neužil,et al.  Microfluidic Technology for Clinical Applications of Exosomes , 2019, Micromachines.

[54]  J. LaBaer,et al.  A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells. , 2019, Cancer research.

[55]  M. Gerlinger,et al.  CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids , 2019, Journal of Immunotherapy for Cancer.

[56]  Seok Chung,et al.  Macrophages‐Triggered Sequential Remodeling of Endothelium‐Interstitial Matrix to Form Pre‐Metastatic Niche in Microfluidic Tumor Microenvironment , 2019, Advanced science.

[57]  John Greenman,et al.  A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform , 2019, BMC Cancer.

[58]  A. Toubert,et al.  Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment , 2019, Journal of Immunotherapy for Cancer.

[59]  G. Bakker,et al.  The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture , 2019, bioRxiv.

[60]  T. Becker,et al.  Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status , 2019, PloS one.

[61]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[63]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2019, Cell.

[64]  S. George,et al.  Microfluidic device to attain high spatial and temporal control of oxygen , 2018, PloS one.

[65]  D. Beebe,et al.  Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model , 2018, Oncoimmunology.

[66]  Chiara Sabatti,et al.  Organoid Modeling of the Tumor Immune Microenvironment , 2018, Cell.

[67]  C. Rice,et al.  Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids , 2018, Cell.

[68]  E. Liu,et al.  Mouse Models for Cancer Immunotherapy Research. , 2018, Cancer discovery.

[69]  Matthew R. DeWitt,et al.  Vascularized microfluidic platforms to mimic the tumor microenvironment , 2018, Biotechnology and bioengineering.

[70]  Roger D Kamm,et al.  3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. , 2018, Lab on a chip.

[71]  S. Sidhu,et al.  Humanized Mice for the Study of Immuno-Oncology. , 2018, Trends in immunology.

[72]  Hans Clevers,et al.  Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids , 2018, Cell.

[73]  Yeonseok Chung,et al.  Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance , 2018, Experimental & Molecular Medicine.

[74]  L. Goulart,et al.  Comparative Assay of 2D and 3D Cell Culture Models: Proliferation, Gene Expression and Anticancer Drug Response. , 2018, Current pharmaceutical design.

[75]  R. Hynes,et al.  Inflamed neutrophils sequestered at entrapped tumor cells via chemotactic confinement promote tumor cell extravasation , 2018, Proceedings of the National Academy of Sciences.

[76]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[77]  A. Abate,et al.  An Ultrahigh-throughput Microfluidic Platform for Single-cell Genome Sequencing , 2018, Journal of visualized experiments : JoVE.

[78]  H. Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[79]  Mark M. Davis,et al.  Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. , 2018, Cell stem cell.

[80]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[81]  Douglas B. Evans,et al.  Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models , 2018, BMC Cancer.

[82]  N. Varadarajan,et al.  Single-cell technologies for profiling T cells to enable monitoring of immunotherapies. , 2018, Current opinion in chemical engineering.

[83]  S. Orkin,et al.  Mapping the Mouse Cell Atlas by Microwell-Seq , 2018, Cell.

[84]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[85]  Shuang Hou,et al.  NanoVelcro rare‐cell assays for detection and characterization of circulating tumor cells☆ , 2018, Advanced drug delivery reviews.

[86]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[87]  F. Nicolantonio,et al.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth , 2017, Nature.

[88]  C. Paweletz,et al.  CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. , 2017, Cancer discovery.

[89]  J. Segall,et al.  Microfluidic modeling of the biophysical microenvironment in tumor cell invasion. , 2017, Lab on a chip.

[90]  Takehiko Kitamori,et al.  Integrated Microfluidic Platform with Multiple Functions To Probe Tumor-Endothelial Cell Interaction. , 2017, Analytical chemistry.

[91]  Aviv Regev,et al.  Massively-parallel single nucleus RNA-seq with DroNc-seq , 2017, Nature Methods.

[92]  A. Vasan,et al.  A microfluidic platform for drug screening in a 3D cancer microenvironment. , 2017, Biosensors & bioelectronics.

[93]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[94]  Li-Hsin Han,et al.  Modeling Physiological Events in 2D vs. 3D Cell Culture. , 2017, Physiology.

[95]  Marion Procter,et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer , 2017, The New England journal of medicine.

[96]  S. Memarzadeh,et al.  Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. , 2017, Stem cells and development.

[97]  Herman Yeger,et al.  Combination therapy in combating cancer , 2017, Oncotarget.

[98]  Wei Wei,et al.  Microchip-based single-cell functional proteomics for biomedical applications. , 2017, Lab on a chip.

[99]  A. Butte,et al.  xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.

[100]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[101]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[102]  Joel A. Yates,et al.  Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling , 2016, Scientific Reports.

[103]  J. Smith-Drake,et al.  Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. , 2016 .

[104]  C. Klein,et al.  A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents , 2016, Cancer Immunology, Immunotherapy.

[105]  S. Tasoglu,et al.  A Bioprinted Liver-on-a-Chip for Drug Screening Applications. , 2016, Trends in biotechnology.

[106]  Ji‐Hyun Lee,et al.  Co-Culture of Tumor Spheroids and Fibroblasts in a Collagen Matrix-Incorporated Microfluidic Chip Mimics Reciprocal Activation in Solid Tumor Microenvironment , 2016, PloS one.

[107]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[108]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[109]  E. Solary,et al.  Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems? , 2016, Biochimica et biophysica acta.

[110]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[111]  Lisa M. Coussens,et al.  The Basis of Oncoimmunology , 2016, Cell.

[112]  Roger D Kamm,et al.  Elucidation of the Roles of Tumor Integrin β1 in the Extravasation Stage of the Metastasis Cascade. , 2016, Cancer research.

[113]  Yang Yang,et al.  A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. , 2016, Lab on a chip.

[114]  Pranav Joshi,et al.  High Content Imaging (HCI) on Miniaturized Three-Dimensional (3D) Cell Cultures , 2015, Biosensors.

[115]  P. Liu,et al.  Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment , 2015, Oncotarget.

[116]  Harjeet Singh,et al.  Automated profiling of individual cell-cell interactions from high-throughput time-lapse imaging microscopy in nanowell grids (TIMING) , 2015, Bioinform..

[117]  S. Verbridge,et al.  Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline. , 2015, ACS biomaterials science & engineering.

[118]  M. Sánchez-Beato,et al.  Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. , 2015, Cancer treatment reviews.

[119]  Aufried T. M. Lenferink,et al.  The detection of EpCAM+ and EpCAM– circulating tumor cells , 2015, Scientific Reports.

[120]  J. Koch,et al.  Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids , 2015, BMC Cancer.

[121]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[122]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[123]  T. Mukohara,et al.  Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. , 2015, Oncology reports.

[124]  S. Friend,et al.  Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. , 2015, Cancer discovery.

[125]  Christopher J. Sevinsky,et al.  Emerging Understanding of Multiscale Tumor Heterogeneity , 2014, Front. Oncol..

[126]  C. Unger,et al.  Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. , 2014, Advanced drug delivery reviews.

[127]  Philip Levy Ho,et al.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance , 2014, Nature.

[128]  Matthew T. Leslie,et al.  Methods to study the tumor microenvironment under controlled oxygen conditions. , 2014, Trends in biotechnology.

[129]  A. Markham.  Idelalisib: First Global Approval , 2014, Drugs.

[130]  Sarah A Heerboth,et al.  Drug Resistance in Cancer: An Overview , 2014, Cancers.

[131]  D. Ingber,et al.  Microfluidic organs-on-chips , 2014, Nature Biotechnology.

[132]  K. Polyak,et al.  Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity , 2014, Nature.

[133]  Diane M Simeone,et al.  Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. , 2014, Lab on a chip.

[134]  D. Beebe,et al.  The present and future role of microfluidics in biomedical research , 2014, Nature.

[135]  Sharon Gerecht,et al.  Going with the flow: microfluidic platforms in vascular tissue engineering. , 2014, Current opinion in chemical engineering.

[136]  F. Cameron,et al.  Ibrutinib: First Global Approval , 2014, Drugs.

[137]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[138]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[139]  Tony Tran,et al.  Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. , 2013, Translational oncology.

[140]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[141]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[142]  Duc-Huy T Nguyen,et al.  Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro , 2013, Proceedings of the National Academy of Sciences.

[143]  A. Mikos,et al.  Modeling Ewing sarcoma tumors in vitro with 3D scaffolds , 2013, Proceedings of the National Academy of Sciences.

[144]  A. Khademhosseini,et al.  Gradients of physical and biochemical cues on polyelectrolyte multilayer films generated via microfluidics. , 2013, Lab on a chip.

[145]  V. Virador,et al.  In vitro three‐dimensional (3D) models in cancer research: An update , 2013, Molecular carcinogenesis.

[146]  Ismail Emre Araci,et al.  Microfluidic very large scale integration (mVLSI) with integrated micromechanical valves. , 2012, Lab on a chip.

[147]  Brendon M. Baker,et al.  Deconstructing the third dimension – how 3D culture microenvironments alter cellular cues , 2012, Journal of Cell Science.

[148]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[149]  Christopher J Murphy,et al.  Integration of basal topographic cues and apical shear stress in vascular endothelial cells. , 2012, Biomaterials.

[150]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[151]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[152]  Mikala Egeblad,et al.  Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. , 2012, Cancer cell.

[153]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[154]  J. Kutok,et al.  Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model , 2012, Cell.

[155]  Hyungil Jung,et al.  Monitoring the status of T-cell activation in a microfluidic system. , 2011, The Analyst.

[156]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[157]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[158]  Ravi A. Desai,et al.  Mechanical regulation of cell function with geometrically modulated elastomeric substrates , 2010, Nature Methods.

[159]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[160]  L. Kunz-Schughart,et al.  Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.

[161]  Gwo-Bin Lee,et al.  Microfluidic cell culture systems for drug research. , 2010, Lab on a chip.

[162]  Emily Burdett,et al.  Engineering tumors: a tissue engineering perspective in cancer biology. , 2010, Tissue engineering. Part B, Reviews.

[163]  Dietmar W Hutmacher,et al.  Biomaterials offer cancer research the third dimension. , 2010, Nature materials.

[164]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[165]  D. Beebe,et al.  Biological implications of polydimethylsiloxane-based microfluidic cell culture. , 2009, Lab on a chip.

[166]  Mark W. Tibbitt,et al.  Hydrogels as extracellular matrix mimics for 3D cell culture. , 2009, Biotechnology and bioengineering.

[167]  Roger D Kamm,et al.  Nanointerstice-driven microflow. , 2009, Small.

[168]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[169]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[170]  Tim Schenkel,et al.  T cell activation on a single-cell level in dielectrophoresis-based microfluidic devices. , 2008, Journal of chromatography. A.

[171]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[172]  A. Ashworth,et al.  Targeted therapy for cancer using PARP inhibitors. , 2008, Current opinion in pharmacology.

[173]  D. Beebe,et al.  Managing evaporation for more robust microscale assays. Part 1. Volume loss in high throughput assays. , 2008, Lab on a chip.

[174]  H. Aarstad,et al.  Co‐culture of Head and Neck Squamous Cell Carcinoma Spheroids with Autologous Monocytes Predicts Prognosis , 2008, Scandinavian journal of immunology.

[175]  N. Kotov,et al.  Three-dimensional cell culture matrices: state of the art. , 2008, Tissue engineering. Part B, Reviews.

[176]  J. Bamburg,et al.  ADF/cofilin family proteins control formation of oriented actin-filament bundles in the cell body to trigger fibroblast polarization , 2007, Journal of Cell Science.

[177]  F. Pampaloni,et al.  The third dimension bridges the gap between cell culture and live tissue , 2007, Nature Reviews Molecular Cell Biology.

[178]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[179]  L. Terracciano,et al.  Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes , 2007, British Journal of Cancer.

[180]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[181]  D. Beebe,et al.  PDMS absorption of small molecules and consequences in microfluidic applications. , 2006, Lab on a chip.

[182]  Diana Kazolias,et al.  Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.

[183]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[184]  G. Whitesides.  The origins and the future of microfluidics , 2006, Nature.

[185]  M. Smyth,et al.  Eradication of established tumors in mice by a combination antibody-based therapy , 2006, Nature Medicine.

[186]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[187]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[188]  J. Peterse,et al.  Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.

[189]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[190]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[191]  Klaus Ley,et al.  Chemokines and chemokine receptors in leukocyte trafficking. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[192]  L. Griffith,et al.  A microfabricated array bioreactor for perfused 3D liver culture. , 2002, Biotechnology and bioengineering.

[193]  Pierre Validire,et al.  Impact of human bladder cancer cell architecture on autologous T‐lymphocyte activation , 2002, International journal of cancer.

[194]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[195]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[196]  M. Sanderson,et al.  Establishment and Analysis of a 3D Co-Culture Spheroid Model of Pancreatic Adenocarcinoma for Application in Drug Discovery. , 2019, Methods in molecular biology.

[197]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[198]  Y. Tabata,et al.  A cancer invasion model combined with CAF aggregates incorporating GM containing a p53 inhibitor. , 2019, Tissue engineering. Part C, Methods.

[199]  Zhi Wei,et al.  Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.

[200]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[201]  A. Mikos,et al.  A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. , 2016, Biomaterials.

[202]  C. Kuo,et al.  An Air-Liquid Interface Culture System for 3D Organoid Culture of Diverse Primary Gastrointestinal Tissues. , 2016, Methods in molecular biology.

[203]  R. Kamm,et al.  Microfluidics: A new tool for modeling cancer-immune interactions. , 2016, Trends in cancer.

[204]  R. Matkowski,et al.  Circulating Tumor , 2014 .

[205]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.